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Oleanolic acid: a promising 
neuroprotective agent for cerebral 
ischemia
Stroke is considered the most common and severely disabling neu-
rological disease. It is one of the leading causes of death after heart 
disease and cancer, causing 10% deaths worldwide and involving 
risk factors such as smoking, obesity and nutritional disbalance. 
Disability affects 75% of stroke survivors through severe mental 
and/or physical impairment depending on the affected brain area 
(Go et al., 2014).
Stroke treatment is limited to thrombolysis and antiplatelet 
therapy with a tissue plasminogen activator (tPA), which is only 
useful if administered within 3 hours of the appearance of early 
symptoms. This therapy is only used in 1–2% stroke patients and 
has, indeed, limited clinical success, as it does not protect neurons 
from the hypoxic insult. Therefore, the development and evalua-
tion of new drugs to reduce the life-threatening effects of stroke 
and hypoxia might prove extremely fruitful.
Stroke is produced by a decrease in blood supply due to different 
types of alterations in the brain blood vessels, which cause cerebral 
hypoxia/ischemia. In turn, the hypoxic damage produces several 
changes in gene expression patterns in brain tissue cells (neurons 
and glial cells). Rapid thrombolysis is effective in protecting the 
injured ischemic core, although preventing the pathological fea-
tures that produce neuronal death requires the development of new 
treatments and the implementation of a dual therapy combining 
the disruption of the clot and the preservation of neuronal func-
tion. In this respect, many preclinical studies have been successful 
in finding neuroprotective agents, but subsequent clinical trials 
have rendered disappointing results.
Inflammation is one of the distinctive events in stroke, while 
microglial cells are the predominant inflammatory effectors in 
brain. Reactive astrocytosis and the formation of a glial scar in the 
boundary zone of the ischemic core are also critical events which 
can produce both positive and negative consequences.
Diet and fatty acid consumption are risk factors associated 
with the development of obesity, cardiovascular disease and can-
cer. In Mediterranean countries, where olive oil is the principal 
source of fat, the incidence of these pathologies is lower than in 
the United States (Lopez-Miranda et al., 2010). Although these 
benefits of the Mediterranean diet have been attributed to its 
high content of monounsaturated fatty acids, a wide variety of 
minor components, such as triterpenes and phenolic compounds, 
are under evaluation.
For centuries, natural triterpenoids have been used as antioxi-
dant and anti-inflammatory agents. 3b-hydroxyolean-12-en-28-
oic acid, known as oleanolic acid (OA), is a well characterized 
triterpenoid present in medicinal plants, fruits, herbs and olive oil 
such as Olea europaea, Calendula officinalis, and Viscum album L 
(Pollier and Goossens, 2012). Traditional Chinese medicine claims 
that OA helps to balance the “yin” fluids of the body, while regu-
lating the “chi”.
Modern medicine also recognizes the therapeutic value of OA. 
Abundant research has shown the therapeutic effects of OA in 
multiple pathologies, from neurodegenerative diseases to infec-
tions and cancer. Regarding neurodegenerative diseases, animal 
models of amyotrophic lateral sclerosis, multiple sclerosis, Parkin-
son’s disease, Huntington’s disease, Alzheimer’s disease and cere-
bral ischemia, among others, have been used to test the protective 
activities of OA and other synthetic triterpenoids, improving 
motor performance and slowing disease progression (Martin et 
al., 2010, 2012; Zhang et al., 2012).
Recent data suggest that OA and its derivatives are also useful in 
preventing and treating type 2 diabetes and related complications 
(fatty liver disease, nephropathy, retinopathy and atherosclerosis). 
The molecular mechanisms proposed for these effects are the 
improvement of insulin signaling and the reduction of hyper-
glycemia, the up-regulation of anti-oxidants and the reduction 
of inflammatory processes (Camer et al., 2014). Also, anti-tumor 
activities of OA analogs have been described in animal cancer 
models and in human breast cancer cells lines, showing a reduc-
tion in angiogenesis and cell proliferation and inducing apoptosis 
(Shanmugam et al., 2014). 
The protective role of triterpenoids, especially OA, has been 
studied using different in vitro and in vivo models of cerebral 
ischemia such as oxygen-glucose deprivation in neuronal primary 
cultures and global or focal ischemia in rodents. In 2012, Zhang 
and collaborators demonstrated that the intraperitoneal admin-
istration of triterpenoids reduced mortality, neurological deterio-
ration and infarct brain area by inducing the expression of heme 
oxygenase-1 (Zhang et al., 2012).
As a hypoxic consequence, free radicals are generated which 
damage DNA and proteins and induce cellular damage and subse-
quent death. One of these free radicals is nitric oxide, produced by 
nervous tissue cells including neurons. Although OA is not a free 
radical scavenger, it reduces cellular oxidative stress response. The 
mechanism of action proposed for OA involves the up-regulation 
of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcrip-
tion factor that increases the expression of antioxidant enzymes 
and the synthesis of glutathione and inhibits the expression of nu-
clear factor κB (NF-κB). Nrf2 is normally inactivated by Keap1 in 
cytoplasm. However, in the presence of triterpenoids such as OA, 
Nrf2 is phosphorylated by different protein kinase pathways and is 
liberated from Keap1 and traslocated to the nucleus to up-regulate 
the expression of antioxidant processes (Loboda et al., 2012). 
Our studies have focused on the role of neuroprotective agents 
in experimental models of hypoxia. In particular, we developed a 
model of focal chemical hypoxia in rats which mimics the effects 
of cerebral ischemia by inducing the expression and stabilization 
of the hypoxia-inducible factor 1α (hif-1α), neuronal damage and 
glial reaction. By using a low OA dose (6 mg/kg per day) adminis-
tered before and after the hypoxic injury, we observed a decrease 
in neuronal degeneration and glial reaction (Caltana et al., 2014).
These results could be related to a reduction (Figure 1) in the 
activity of neuronal nitric oxide synthase (nNOS) and inducible 
nitric oxide synthase (iNOS) in microglial cells, both of which 
decreased with OA exposure in hypoxic animals. Therefore, acting 
through the activation of Nrf2, OA reduces (Figure 2) the expres-
sion of nNOS and iNOS in the hypoxic brain, protecting neurons 
against the oxidative damage triggered by microglial cells. We also 
showed an astrocytic reaction involving high levels of protein 
S100β which could stimulate the uptake of excitotoxic levels of 
glutamate and prevent neuronal damage, while also inducing the 
recovery of cytoskeletal protein assembly and thus stabilize cell 
morphology and function. 
Although experimental data is still required, growing evidence 
demonstrates the beneficial consequences of OA in the prevention 
and treatment of different neuropathologies. The enrichment of 
food and diet with this compound could prove a useful tool in 
health and quality of life improvement and decrease the incidence 
of frequent pathologies such as vascular diseases.
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Figure 1 Photomicrographs showing neurons (A, D, G), astrocytes (B, e, H) 
and microglial cells (C, F, I) in different experimental conditions.
Hypoxia induces neuronal degeneration with loss of dendritic trees (D) and 
glial reaction – astrocytosis (E) and microglial activation (F). The pretreat-
ment with oleanolic acid (OA) decreases neuronal damage (G), astrocytic 
reaction (H) and microglial activation (I). (A–C) Normoxic conditions. (D–
F) Hypoxic coditions. (G–I) Pretreatment with OA and hypoxic conditions. 
Immunofluorescence for 200 kDa neurofilaments in A, D, and G, and for 
gliofribrillary acidic protein in B, E and H. Histochemical staining for mi-
croglial cells (C, F and I) was made with tomato lectin. Scale bar: 15 μm.
Figure 2 Schematic representation of cellular processes occurring in the 
hypoxic brain and the effects of oleanolic acid (OA) pretreatment. 
Hypoxia induces the activation of microglial cells, which suffer morpholog-
ical transformations and become ameboid-shaped. The activated microglial 
cells release proinflammatory cytokines and reactive oxygen species (ROS) 
such as nitric oxide, which induce astroglial reaction and neuronal damage. 
OA reduces microglial reaction and then decreases astroglial reaction, thus 
protecting neuron morphology and function. Gray arrows indicate the ef-
fects of hypoxia on neurons, astrocytes and microglial cells. Orange arrows 
indicate inflammatory effects on nervous tissue cells. Yellow arrows indicate 
OA preventive effects.
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